Publications by the researcher in collaboration with Felipe Prosper Cardoso (11)

2025

  1. Clinical significance of complete remission and measurable residual disease in relapsed/refractory multiple myeloma patients treated with T-cell redirecting immunotherapy

    American Journal of Hematology, Vol. 100, Núm. 1, pp. 93-102

  2. Forimtamig, a novel GPRC5D-targeting T-cell bispecific antibody with a 2+1 format, for the treatment of multiple myeloma

    Blood, Vol. 145, Núm. 2, pp. 202-219

2024

  1. Biomarkers of Efficacy and Safety of the Academic BCMA-CART ARI0002h for the Treatment of Refractory Multiple Myeloma

    Clinical Cancer Research, Vol. 30, Núm. 10, pp. 2085-2096

  2. Immune dysfunction prior to and during vaccination in multiple myeloma: a case study based on COVID-19

    Blood Cancer Journal, Vol. 14, Núm. 1

  3. Molecular mechanisms promoting long-term cytopenia after BCMA CAR-T therapy in multiple myeloma

    Blood Advances, Vol. 8, Núm. 21, pp. 5479-5492

  4. Targeting CD38 with isatuximab and a novel CD38/CD3×CD28 trispecific T-cell engager in older patients with acute myeloid leukemia

    Blood Advances

2023

  1. Fractionated initial infusion and booster dose of ARI0002h, a humanised, BCMA-directed CAR T-cell therapy, for patients with relapsed or refractory multiple myeloma (CARTBCMA-HCB-01): a single-arm, multicentre, academic pilot study

    The Lancet Oncology, Vol. 24, Núm. 8, pp. 913-924

2021

  1. Immune biomarkers to predict SARS-CoV-2 vaccine effectiveness in patients with hematological malignancies

    Blood Cancer Journal, Vol. 11, Núm. 12

2020

  1. Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma

    Blood, Vol. 136, Núm. 2, pp. 199-209

2019

  1. The mechanism of action of the anti-CD38 monoclonal antibody isatuximab in multiple myeloma

    Clinical Cancer Research, Vol. 25, Núm. 10, pp. 3176-3187

2017

  1. Target Expression, Generation, Preclinical Activity, and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM801 for Multiple Myeloma Treatment

    Cancer Cell, Vol. 31, Núm. 3, pp. 396-410